Fluticasone Propionate

CHEMBL1473 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
500.6 g/mol
LogP
4.0
Phase
4

This corticosteroid is widely used as an inhaler for asthma prevention and as a nasal spray for allergic rhinitis, working by suppressing the inflammatory response in the respiratory tract. When applied topically to the skin, it also treats eczema, psoriasis, and other inflammatory skin conditions.

Masse moléculaire

500,6000 g/mol

LogP

4,00

TPSA

106,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

InChI

InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

Molecular Formula

C25H31F3O5S

HBD / HBA

1 / 9

Liaisons Rotatives

6

Atomes Lourds

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This corticosteroid is widely used as an inhaler for asthma prevention and as a nasal spray for allergic rhinitis, working by suppressing the inflammatory response in the respiratory tract. When applied topically to the skin, it also treats eczema, psoriasis, and other inflammatory skin conditions.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Fluticasone Propionate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1473. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 444036. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.